CPT code 90593 identifies a recombinant chikungunya virus vaccine administered intramuscularly to prevent chikungunya infection. As chikungunya vaccination becomes part of clinical prevention strategies, a distinct CPT code for the vaccine product is important for standardized reporting, coverage determinations, and national immunization program planning. The code covers the vaccine product itself rather than separate administration-only services.

Key payers included in this national overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical purpose of the vaccine, common sites of service for administration, and the payer landscape addressed in the analysis. The publication summarizes coding implications, typical billing considerations, and how payers approach coverage and claims processing for new vaccine products.

This summary provides clinicians, billing teams, and policy stakeholders with a concise reference on CPT code 90593, what it represents clinically, and what to expect in payer coverage discussions. Data not available in the input is noted where applicable, and the main content focuses on benchmarks, policy updates, and the clinical context surrounding deployment of a recombinant chikungunya vaccine at the national level.